We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
For its first 15 years, Nexus Pharmaceuticals has relied on contractors to manufacture the sterile injectable meds it develops. Figuring it is high time to do that itself, the Chicago-area company has launched a $250 million project that will give it that
Nexus Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial.....